Rare disease
Stories
-
FDA approves pimicotinib for adults with symptomatic tenosynovial giant cell tumor
The FDA approved pimicotinib (Pimjetmi) on November 10, 2026, after an overall response rate of 56% versus 3.2% on placebo at Week 25. For adults with symptomatic TGCT, an approved kinase inhibitor now exists.
-
Orphalan opens China sites in Phase 3 Wilson disease trial and randomizes first participant
Orphalan said three Chinese hospitals are now recruiting for its 38-participant TRADITiONAL Phase 3 study of once-daily trientine tetrahydrochloride. Wilson disease patients aged 8 years and older can now enroll in the United States and China.
-
FDA approves Voceryq for adults with recurrent respiratory papillomatosis
Seven of 26 adults with at least three baseline surgeries (27%) needed no surgery in the first year after Voceryq, the FDA said in granting accelerated approval. Adults with recurrent respiratory papillomatosis now have a plasmid DNA-based immunotherapy approved in the U.S.
-
On crovalimab, 59.5 percent of treatment-naive aHUS participants had a complete TMA response
In the Phase III COMMUTE-a study, 59.5 percent of 37 treatment-naive participants with aHUS had a complete thrombotic microangiopathy response through Week 25, the registry shows. The record covers 83 participants in three cohorts.
-
Vertex posts Phase 3 ELX/TEZ/IVA study results in infants with cystic fibrosis
Vertex Pharmaceuticals Incorporated posted results of a Phase 3 open-label study of ELX/TEZ/IVA in cystic fibrosis participants 12 to less than 24 months of age. The study enrolled 67 participants.
-
ACADIA posts Phase 3 carbetocin nasal spray results in Prader-Willi syndrome
ACADIA Pharmaceuticals Inc. posted results of a 12-week Phase 3 study of carbetocin nasal spray against placebo in hyperphagia in Prader-Willi syndrome. The study enrolled 175 participants.
-
FDA approves Emcitate, the first treatment for MCT8 deficiency
Egetis Therapeutics' tiratricol treats the excess blood thyroid hormone of Allan-Herndon-Dudley syndrome. The company also received a rare pediatric disease priority review voucher.
-
FDA approves Fayuvi, the first gene therapy for Sanfilippo syndrome type A
Ultragenyx's one-time AAV9 infusion received standard full approval for children with MPS IIIA, and the company received a priority review voucher.